You are here

Enhanced Canine Performance, Protection and Survivability

Award Information
Agency: Department of Defense
Branch: Special Operations Command
Contract: H92222-18-P-0008
Agency Tracking Number: S172-002-0085
Amount: $149,505.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: SOCOM172-002
Solicitation Number: 2017.2
Timeline
Solicitation Year: 2017
Award Year: 2018
Award Start Date (Proposal Award Date): 2017-11-28
Award End Date (Contract End Date): 2018-05-29
Small Business Information
567 Aspen Rd
Birmingham, MI 48009
United States
DUNS: 080610398
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 David Livingston
 (617) 820-6822
 david.l@metrobiotech.com
Business Contact
 Sean Riley
Phone: (540) 905-5052
Email: Sean@libertybiosecurity.com
Research Institution
N/A
Abstract

Given the benefits of exercise on general health, orally active compounds that can mimic or potentiate the effects of exercise have been of keen interest as therapeutic and dietary ingredients. Our proposed approach for enhancement of USSOCOM Multi-Purpose Canine (MPC) endurance and sensory performance using an exercise mimetic is based on the observation that age-related decline of nicotinamide adenine dinucleotide (NAD+) can cause impaired muscle function and sensory performance in mammals. We have discovered that supplementation with NAD+ precursors in rodents can improve muscle performance and neovascularization of myofibrils. Nicotinamide mononucleotide (NMN) is a naturally occurring molecule that is produced by endogenous biosynthetic pathways. Administration of our formulated, proprietary NMN restored muscle microvasculature and exercise capacity in aged mice, and may also enhance the endurance and recovery of USSOCOM MPCs. The work proposed in this Phase 1 study will deliver a validated canine whole blood or serum assay to detect NMN and its metabolites, allowing us to examine dose-response pharmacokinetic and pharmacodynamic relationships in Phase 2 MPC performance studies. In Phase 1, we will also design repeat dose performance and safety studies in MPCs to be performed in Phase 2, using data from our completed rodent model studies.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government